Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Vanda Pharmaceuticals (VNDA) reported a Q4 loss of $0.08 per share, which was better than the Zacks Consensus Estimate of a $0.14 loss. This is a larger loss compared to the $0.04 per share loss from the previous year.
February 13, 2025 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vanda Pharmaceuticals reported a Q4 loss of $0.08 per share, better than the expected $0.14 loss, but worse than last year's $0.04 loss.
The better-than-expected earnings per share loss suggests a positive short-term impact on VNDA's stock price, as it indicates the company is performing better than analysts anticipated. However, the larger loss compared to last year may temper some of the positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100